Pepgen announces positive data from low-dose cohort of pgn-edo51 in ongoing connect1-edo51 phase 2 clinical trial for treatment of duchenne muscular dystrophy

Boston--(business wire)--pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced positive clinical data from the first dose cohort (5 mg/kg) of pgn-edo51, its lead investigational candidate for patients with duchenne muscular dystrophy (dmd) whose mutations are amenable to an exon 51-skipping approach. in the ongoing.
PEPG Ratings Summary
PEPG Quant Ranking